Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CCX507-B
- Development stage
- Phase 1
- Lead developer
- Amgen
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CCX507-B is an orally administered small molecule inhibitor of the C-C chemokine receptor type 9 (CCR9), developed by ChemoCentryx as a second-generation treatment for inflammatory bowel diseases (IBD). CCR9 is a chemokine receptor primarily expressed on gut-homing T cells, and its interaction with the ligand CCL25 (TECK) is critical for the recruitment of these cells to the intestinal mucosa. By blocking CCR9, CCX507-B aims to reduce intestinal inflammation in conditions such as Crohn's disease and ulcerative colitis. The "-B" suffix likely refers to a specific salt or formulation used in clinical development. In Phase I studies, the compound demonstrated dose-proportional pharmacokinetics and high occupancy of CCR9 on circulating leukocytes.
- Other names
- CCX507-BCCX-507-BCCX 507-B
02
Targets
CCR9 (C-C chemokine receptor type 9)
Beyond the preview
Go deeper on CCX507-B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CCX507-B.